Oradin is a preparation of loratadine. Loratadine is a long acting tricyclic antihistamine with selective peripheral H1 receptor antagonistic activity and no central sedative or anticholinergic effect.

Oradin provides fast effective relief from the symptoms of hay fever, allergic rhinitis such as sneezing, nasal discharge, itching, ocular itching and burning. Nasal and ocular signs and symptoms are relieved rapidly after oral administration. Oradin is also indicated for the relief of the symptoms associated with chronic idiopathic urticaria. In children over 2 years Oradin is indicated for the symptomatic relief of seasonal allergic rhinitis and allergic skin conditions such as urticaria, nettle-rash.

Tablet:
Adult and children over 12 years of age: One tablet, once daily when symptoms require treatment.
Children of 2-12 years of age (Body weight more than 30 kg): one tablet once daily.
Children of 2-12 years of age (Body weight less than 30kg): half tablet once daily. 

Suspension:
Adult and children over 12 years of age: 2 teaspoonful (10 ml) of suspension once daily.
Children of 2-12 years of age (Body weight more than 30 kg): 2 teaspoonful (10 ml) of suspension once daily.
Children of 2-12 years of age (Body weight less than 30kg): 1 teaspoonful (5 ml) of suspension once daily.
Below 2 years of age: Safety and efficacy of Oradin has not been established.
 

Loratadine is contraindicated in patients who have shown hypersensitivity or idiosyncrasy to their components.

There is no experience of the use of loratadine in human pregnancy, hence it should not to be used during pregnancy. Loratadine is excreted in breast milk, so it should not be administered to lactating mother.

During controlled clinical studies the incidence of adverse events including sedation and anticholinergic effects observed with 10 mg loratadine was comparable to that observed with placebo. Fatigue, nausea and headache were reported rarely.
Scientific studies show that loratadine does not cause drowsiness. It does not affect performance and ability to drive or tasks requiring concentration.

When administered concurrently with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies. Interactions with other drugs have not been reported.

In the event of overdose, treatment which should be started immediately is symptomatic and supportive. The patient should be induced to vomit, even if emesis has occurred spontaneously, but not in the patients with impaired consciousness. Administaration of activated charcoal as a slurry with water may be attempted following emesis. If vomiting is unsuccessful or contraindicated, gastric lavage should be performed.

Store in a cool, dry place and protect from light. Keep out of reach of children.

Oradin tablet: Box containing 10 strips of 10 tablets each. Each tablet contains loratadine USP 10mg.
Oradin FT tablet: Box containing 4 strips of 10 flash tablets each. Each flash tablet contains loratadine USP 10mg.
Oradin suspension: Bottle containing 60 ml suspension. Each 5 ml contains loratadine USP 5 mg. 



Manufactured by:
ESKAYEF BANGLADESH LTD
DHAKA, BANGLADESH
® REGD.TRADEMARK